Abiopharma

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Disclosure of Changes in Interest of Director and Substantial Shareholder - Mr. Lim Yingjie Eugene

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Employee Stock Option/ Share Scheme: Notice of Use of Treasury Shares

General Announcement: Next Day Disclosure Return

General Announcement: Changes to the Composition of the Board and Board Committees

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice

Autohome Inc. Announces Results of 2025 Annual General Meeting

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Organon Canada et Henlius élargissent l’accès aux traitements à base de dénosumab avec le lancement de BILDYOS® (injection de dénosumab) et de TUZEMTY® (injection de dénosumab), des biosimilaires de PROLIA et de XGEVA